Starting CML Treatment: Collaborative Choices for Better Outcomes
Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies that optimize communication when considering treatment options.
EP: 1.Understanding CML: Your Journey from Diagnosis to Treatment
EP: 2.Navigating CML: Tools to Empower Patients and Caregivers
EP: 3.Empowering CML Caregivers: Strategies and Support Systems
Now Viewing
EP: 4.Starting CML Treatment: Collaborative Choices for Better Outcomes
EP: 5.Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life
EP: 6.When CML Therapy Shifts: Collaborative Approaches to Treatment Changes
EP: 7.CML Treatment: Scenarios that Necessitate Switching Therapy
EP: 8.Ensuring Informed CML Care from Diagnosis Onward
EP: 9.Advancing CML Management Towards an Ideal Patient Journey
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following questions:
- What are some of the most important considerations when starting treatment for a newly diagnosed patient with CML? How do age, comorbidities, and other considerations factor into the treatment plan?
- Describe your best practices in helping newly diagnosed patients with CML better understand their treatment plan given the complexities involved.
- In your experience, what strategies promote transparent communication around treatment considerations?
- How can patients feel empowered to collaborate with their healthcare team to make an informed decision on the optimal initial treatment?
Recent Videos
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
